Research programme: diabetes therapeutics - Pfizer
Alternative Names: GPR119 agonists - Pfizer; JNJ-28630355Latest Information Update: 16 Mar 2022
At a glance
- Originator Arena Pharmaceuticals
- Developer Pfizer
- Class Pyrimidines; Small molecules
- Mechanism of Action G protein-coupled receptor agonists; GPR119 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
- 10 Mar 2011 Research programme: diabetes therapeutics - Arena Pharmaceuticals is available for licensing. http://www.arenapharm.com